ProVen Growth and Income VCT plc
Total Voting Rights
1 October 2026

In conformity with the Disclosure and Transparency Rule 5.6.1, ProVen Growth and Income VCT plc (the “Company”) announces that the Company’s capital and voting rights, as at 30 September 2026, are summarised as follows:

  Shares in issue Voting rights per Share Voting rights
Ordinary shares of 1.6187p each 328,019,357 1 328,019,357
       
Total voting rights     328,019,357
       

The Company does not hold any shares in treasury.

The above takes account of any shares that have been recently bought back for cancellation, even if such transactions have not yet settled.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, ProVen Growth and Income VCT plc under the FCA’s Disclosure Guidance and Transparency Rules.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

– End

ProVen VCT plc
Total Voting Rights
1 October 2026

In conformity with the Disclosure and Transparency Rule 5.6.1, ProVen VCT plc announces that the Company’s capital and voting rights, as at 30 September 2026, are summarised as follows:

  Shares in issue Voting rights per Share Voting rights
Ordinary shares of 10p each 298,575,634 1 298,575,634
       
Total voting rights     298,575,634
       

The Company does not hold any shares in treasury.

The above takes account of any shares that have been recently bought back for cancellation, even if such transactions have not yet settled.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, ProVen VCT plc under the FCA’s Disclosure Guidance and Transparency Rules.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

– End

MONACO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C) and US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D). The dividend for the Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock is for the period from July 15, 2026 to October 14, 2026. The dividend will be paid on October 15, 2026 to all holders of record as of October 14, 2026 of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock.

The Company has also declared a quarterly dividend on its common stock of US $0.125 per share for the quarter ended September 30, 2026. The dividend for the common stock is payable on November 5, 2026, to holders of record of common stock as of October 20, 2026.

The declaration of a dividend is subject to the discretion of the Board of Directors of the Company, and accordingly will depend on, among other things, the Company’s earnings, financial condition and cash requirements and availability, the Company’s ability to obtain debt and equity financing on acceptable terms as contemplated by the Company’s growth strategy, the restrictive covenants in the Company’s existing and future debt instruments and global economic conditions.

About Costamare Inc.

Costamare Inc. is one of the world’s leading owners and providers of containerships for charter. The Company has 52 years of history in the international shipping industry and a fleet of 69 containerships in the water, with a total capacity of approximately 520,000 TEU. The Company also has 22 newbuild containerships under construction and has agreed to acquire two secondhand containerships, which together represent a total capacity of approximately 152,600 TEU. The Company also participates in a lease financing business. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C” and “CMRE PR D”, respectively.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could” and “expect” and similar expressions. These statements are not historical facts but instead represent only the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-34934) under the caption “Risk Factors”.

Company Contacts:
Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development, Investor Relations

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: ir@costamare.com

— Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients —

— Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period —

— Radiological assessment shows trend for fibrotic stricture stabilization over treatment course —

— Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) —

— Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months —

— Company to host webcast today at 8:30 a.m. Eastern Time —

Antwerp, Belgium, October 1, 2026 – Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD, a severe manifestation of Crohn’s disease characterized by progressive bowel fibrosis and intestinal strictures.

The OLE study (Part B) evaluated long-term treatment with ontunisertib 200 mg BID on top of standard of care. Of the participants eligible to roll over into the OLE study from the 12-week placebo-controlled Part A of STENOVA, 94% elected to enter the study (n=49).

The results demonstrated a generally favorable long-term safety and tolerability profile of ontunisertib 200 mg BID for up to 60 weeks of treatment, as well as maintenance of the gut-restricted pharmacokinetic (PK) profile observed in Part A of the trial. Sustained disease control, with low symptoms and disease activity scores and radiological stricture stabilization, was also observed. Importantly, a low FSCD-related annualized event rate of 3% was reported in patients treated with ontunisertib 200 mg BID up to 60 weeks.

“Fibrostenosing Crohn’s disease remains one of the most significant unmet needs in fibro-inflammatory bowel disease, with no approved therapies targeting the fibrotic component of the disease,” commented Florian Rieder, MD, Vice-Chair, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic. “Beyond the favorable safety and tolerability profile, what stands out in the OLE results is the sustained disease control as well as the low rate of interventions, with only one EBD and no surgeries reported. Importantly, patients appeared to continue to do well on long-term treatment with ontunisertib, maintaining low symptom levels and favorable outcomes on quality-of-life assessments. In a patient population often facing progressive bowel damage and recurrent procedures, these combined findings point to the potential of ontunisertib to provide a meaningful clinical benefit.”

Philippe Wiesel, Chief Medical Officer of Agomab, added: “We are very pleased with the OLE results announced today. The favorable long-term safety profile, maintenance of gut-restricted exposure and signals of sustained disease control observed over up to 60 weeks of treatment provide strong support for the initiation of our global NOV-ERA Phase 2b study later this year. Importantly, these data further support our belief that targeting fibro-inflammation through a differentiated anti-fibrotic mechanism may address a key driver of disease progression that remains largely untreated today. We look forward to evaluating ontunisertib across multiple dose levels in NOV-ERA as we continue to advance what we believe is a potentially novel therapeutic approach for people living with fibro-inflammatory conditions.”

Topline STENOVA OLE results

Safety and tolerability profile

Ontunisertib 200 mg BID demonstrated a generally favorable safety and tolerability profile through up to 60 weeks of treatment. Five serious adverse events were reported in four patients in Part B of the STENOVA study (48-week OLE); all of which were considered unrelated or unlikely related to study treatment.

There were no signals of cardiac injury, pro-inflammatory effects, vasculitis, liver toxicity or thrombotic events during the extended treatment period.

Pharmacokinetic (PK) profile

Systemic exposure of ontunisertib remained low throughout the OLE period and consistent with observations from the randomized-controlled 12-week portion of STENOVA. Plasma concentrations remained well below IC50 levels, supporting the efficient gut-restricted pharmacokinetic profile of ontunisertib and its differentiated approach to ALK5 inhibition.

Event rate

Only one FSCD-related event, an EBD procedure, was reported during the study, corresponding to an annualized event rate of 3%. No patients progressed to surgery during up to 60 weeks of ontunisertib 200 mg BID treatment. For reference, while not based on head-to-head studies, recent publications on a comparable FSCD patient population receiving advanced therapies reported annualized event rates ranging from 23-35%.1,2,3,4

Imaging results

Magnetic resonance enterography (MRE) assessments performed at Weeks 24 and 48 of the OLE study suggested radiological stabilization of fibrotic strictures over the course of treatment with ontunisertib 200 mg BID. While patients receiving placebo showed a trend of radiological progression during the 12-week Part A of the STENOVA study, the OLE results suggest that when switching to ontunisertib, those patients stabilized and progressively caught up with those already exposed to ontunisertib in Part A.

Given the optional nature of the Week 48 endoscopy assessment in the OLE study, the available data were too limited to allow for a reliable interpretation.

Patient-reported outcomes

Patients maintained a low symptom burden and disease activity throughout the OLE period, with sustained improvements observed across stricture-specific symptom assessments, Crohn’s disease activity score (CDAI) and quality-of-life measures. At Week 48 of the OLE, 97% of evaluable patients were in clinical remission as assessed by the CDAI score.

Next steps with ontunisertib: NOV-ERA Phase 2b study

Agomab recently completed regulatory filings for NOV-ERA, a global Phase 2b trial designed to evaluate ontunisertib in approximately 320 patients with symptomatic FSCD and plans to initiate the study in the coming months. In NOV-ERA, participants will be randomized to receive either ontunisertib at one of three dose levels (400 mg BID, 200 mg BID, and 100 mg BID), or a matching placebo. Together with the favorable safety and tolerability profile previously demonstrated in Phase 1 at doses up to 400 mg BID, the positive safety and tolerability findings of the OLE study provide strong support for the inclusion of a 400 mg BID treatment arm in the NOV-ERA Phase 2b study.

Agomab intends to present detailed STENOVA OLE results at a future scientific conference.

Ontunisertib is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established. 

Webcast Event
The Company will hold a live webcast on Thursday, October 1, 2026 at 8:30 a.m. Eastern Time to discuss the STENOVA OLE results. Members of the Agomab management team will be joined by key opinion leader Dr. Florian Rieder. To register for the live webcast and replay, please visit the Agomab homepage.

About STENOVA
STENOVA, a first-in-indication study, was a two-part Phase 2a trial in Crohn’s patients with symptomatic ileal strictures. Part A was a randomized, double-blind, placebo-controlled study in a total of 103 participants. Participants were randomized to receive either 100mg QD or 200mg BID of ontunisertib or placebo for 12 weeks on top of standard of care, including anti-inflammatory biologics. The study was conducted in investigational sites in the USA, Canada and six European countries. The primary endpoint was the evaluation of the safety and tolerability of ontunisertib in FSCD patients. Secondary endpoints included pharmacokinetics (PK) and target engagement. Exploratory endpoints included the Simple Endoscopic Score of Crohn’s disease (SES-CD) and novel FSCD specific endpoints such as the Stricturing Patient Reported Outcome (S-PRO) score and MRE. Eligible study participants who completed the double-blind 12-week treatment period could participate in the OLE part of the STENOVA study (Part B) and receive ontunisertib 200mg BID for up to an additional 48 weeks. 49 patients rolled over (94% of eligible patients of STENOVA Part A) and 37 patients completed the 48-week OLE Part B of STENOVA. The OLE study assessed the long-term safety and PK profile of ontunisertib and explored the event rate and disease progression in FSCD patients.

About NOV-ERA
The planned NOV-ERA study is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial to assess the efficacy and safety of ontunisertib in participants diagnosed with symptomatic FSCD. The trial is expected to enroll up to 320 adult patients globally. To be eligible for the trial, participants must have at least one naive or anastomotic endoscopically non-passable ileal stricture, confirmed by a centrally read Simple Endoscopic Score for Crohn’s Disease (SES-CD). Upon study initiation, participants will be randomized in a 1:1:1:1 ratio to receive either ontunisertib at one of three dose levels (400 mg, 200 mg, and 100 mg), or a matching placebo, administered twice daily (BID). The trial will consist of a 6-week screening period, a 52-week treatment period, and a 2-week follow-up period. The primary endpoint is the proportion of patients achieving endoscopic passability of the ileal index stricture at Week 24.

About Ontunisertib
Ontunisertib (AGMB-129) is an oral small molecule GI-restricted inhibitor of ALK5 (or TGF-β RI) currently in clinical development for the treatment of Fibrostenosing Crohn’s Disease (FSCD). TGF-β is a major driver of fibrosis. Ontunisertib is specifically designed to inhibit ALK5/TGF-β in the GI-tract. Rapid first-pass metabolism in the liver prevents clinically relevant systemic exposure, potentially delivering an improved safety profile over systemically available inhibitors in this class. Ontunisertib has received U.S. FDA Fast Track Designation.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. “Forward-looking statements” include, without limitation, statements regarding the potential of ontunisertib for Fibrostenosing Crohn’s disease, the expected initiation of the NOV-ERA Phase 2b study, and our interactions with regulatory authorities. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; and disruptions caused by our reliance on third party suppliers and service providers. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu 
Phone: +49 172 861 8540


1 El Ouali et al. 2026, doi:10.1186/s12876-026-04815-4;
2 El Ouali et al. 2022, doi:10.1002/ueg2.12314; and
3 El Ouali et al. 2026, doi:10.1093/ecco-jcc/jjag038.
4 Cross-trial comparisons are inherently limited due to differences in study design, patient populations, treatment regimens, endpoints and other factors, and no conclusions regarding the relative efficacy or safety of ontunisertib should be drawn from such comparisons in the absence of head-to-head clinical trials.

Following the sale and repayment, LFTD Partners Inc. holds more than $2.4 million in cash

KENOSHA, Wis., Oct. 01, 2026 (GLOBE NEWSWIRE) — Lifted Made, a wholly owned subsidiary of LFTD Partners Inc. (OTCQB:LIFD), is pleased to announce that it completed the sale of its former headquarters building at 5511 95th Avenue in Kenosha, Wisconsin, on September 29, 2026, for $1.5 million. Lifted Made used $841,110 of the proceeds to repay all of its outstanding bank debt.

Following the sale and debt repayment, LFTD Partners Inc. held more than $2.4 million in cash on hand.

In connection with the sale, Lifted Made consolidated the operations previously conducted at its former headquarters building into its existing leased facilities in Kenosha, which total 41,025 square feet.

Jake Jacobs, President and CFO of LFTD Partners Inc., commented: “This transaction strengthens our financial flexibility as we navigate continued regulatory uncertainty in the hemp industry. As of September 30, LFTD Partners’ consolidated cash on hand exceeds our company’s stock market capitalization by almost $1 million.”

About LFTD Partners Inc.
LFTD Partners Inc. (OTCQB: LIFD), Jacksonville, FL, through its wholly owned subsidiary, Lifted Made, Kenosha, WI, develops, manufactures and markets branded consumer products, including award-winning hemp-derived products and beverages under the Urb and Highlandia brands, and hemp-free health and wellness gummies under the Mielos brand. LFTD Partners also owns a 4.99% non-controlling equity interest in hemp-derived beverage and products company Ablis and in craft distiller Bendistillery, Bend, OR. For more information, please read LIFD’s filings with the U.S. Securities and Exchange Commission, which fully describe LFTD Partners Inc.’s business and the Risk Factors associated therewith.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes the operations, financing, growth, performance, products, plans and expectations of LFTD Partners Inc. and Lifted Liquids, Inc. d/b/a Lifted Made, d/b/a Urb Finest Flowers, d/b/a Highlandia, and d/b/a LM Nutra (together, the “Company”). Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to these companies’ actual operations, financing, growth, performance, products, plans or results of these companies differing materially from those expressed or implied by the forward-looking statements. These risks include changes in federal, state and local laws governing hemp-derived cannabinoid products; federal restrictions enacted under Section 781 of Public Law 119-37, including restrictions on intermediate and final hemp-derived cannabinoid products containing cannabinoids that “are not capable of being naturally produced by a Cannabis sativa L. plant,” a total THC limit of 0.3% on a dry weight basis, including THCA, a limit of 0.4 milligrams per container of final hemp-derived cannabinoid products for the combined total of THC and other cannabinoids with similar effects, and restrictions on products containing cannabinoids that can occur naturally in the cannabis plant but “were synthesized or manufactured outside the plant”; Section 2019 of H.R. 6500, enacted as Public Law 119-103, postponed application of most of these restrictions until December 11, 2026, but the restrictions on products containing cannabinoids that cannot naturally be produced by the cannabis plant remain scheduled to take effect on November 12, 2026, at which time those products would no longer qualify as hemp and would instead be treated as marijuana under federal law; the possibility that these provisions or their effective dates may be amended or delayed; FDA regulation of products containing THC or CBD; the Company’s ability to maintain distributor and retailer relationships; product demand; inventory, manufacturing and supply-chain risks. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain other factors, including the risk factors set forth in LFTD Partners Inc.’s filings with the Securities and Exchange Commission. None of the statements contained herein have been approved by the Food and Drug Administration, and none of the products manufactured or sold by the Company are intended to diagnose, treat, cure or prevent any disease. This press release does not constitute an offer to sell common stock or any other securities of LFTD Partners Inc.

Consumer Notice
Many of the Company’s products contain THC or other intoxicating ingredients. For adults age 21 and older only. Keep out of reach of children and pets. Do not drive or operate machinery after consumption. Do not use if pregnant, nursing or subject to drug testing. Statements in this press release have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Contact Information
William C. “Jake” Jacobs
President and CFO of LFTD Partners Inc.
(847) 400-7660
jakejacobs@LFTDPartners.com

Inaugural close highlights strong institutional demand for asset-backed finance solutions

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Brookfield today announced the final close of Oaktree’s Asset-Backed Finance Fund (“ABF I”) with $2 billion of commitments across the Fund and related investment vehicles, achieving its target fundraise. The Fund attracted a globally diversified base of institutional investors, including U.S. public pension plans and sovereign wealth funds, reflecting strong institutional demand for asset-backed finance solutions. The achievement is in addition to the success of Oaktree’s Asset-Backed vehicle focused on private wealth investors.

Brendan Beer, Oaktree Managing Director and Portfolio Manager, said, “As the private asset-backed market grows, its sheer variety across sectors, structures and risk/return makes the market difficult to navigate. We see that as opportunity, giving us real freedom to pursue the best relative value. Our approach is simple: survey a very broad market for less-crowded lending opportunities, and subject them to Oaktree’s critical eye. The partnership with Brookfield has supercharged our proprietary sourcing and added differentiated perspectives to our investment decisions.”

Oaktree’s ABF strategy focuses on providing flexible capital solutions to originators across a range of sectors including equipment leasing, transportation, consumer, real estate and infrastructure. The close of ABF I builds on Oaktree’s more than two decades of experience in asset-backed finance. Across the broader ABF platform, Oaktree has invested more than $19 billion and developed relationships with hundreds of third-party originators.

ABF I’s final close builds on Brookfield’s longstanding partnership with Oaktree, which dates back to 2019. Now as an integrated business, the strategy benefits from deeper sourcing and underwriting expertise, harnessing Brookfield’s global scale and extensive operating platform. ABF I is complementary to Brookfield’s broader asset-based finance platform, which totals more than $60B and provides differentiated access to opportunities including specialty finance, residential non-qualified mortgages, aviation lending, music royalties, fund finance and digital infrastructure leases.

About Brookfield

Brookfield is a leading global investment firm, headquartered in New York, with more than $1 trillion in assets under management. The firm owns and operates high-quality businesses and real assets that provide essential services and form the backbone of the global economy. Brookfield invests on behalf of institutions and individuals around the world across infrastructure, energy, private equity, real estate, and credit. With more than a century of operating experience and a global presence in over 50 countries, Brookfield deploys long-term capital to generate sustainable value for its clients and shareholders. Brookfield Corporation (NYSE: BN, TSX: BN) and Brookfield Asset Management (NYSE: BAM, TSX: BAM) are publicly traded in New York and Toronto.

For more information, please visit our website at www.brookfield.com.

About Oaktree

As a part of Brookfield’s $416 billion credit platform, Oaktree is a premier global credit manager emphasizing an opportunistic, value-oriented, and risk-controlled approach to investing across credit, equity, and real estate. To learn more about our global business and investment ethos, please visit Oaktree’s website at www.oaktreecapital.com.

Brookfield Media:
Rachel Wood
Tel: (980) 428-3539
Email: rachel.wood@brookfield.com
Brookfield Investor Relations:
Jason Fooks
Tel: (212) 417-2442
Email: jason.fooks@brookfield.com
   

Notice to Readers

This press release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect our current views with respect to, among other things, our operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Brookfield are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, the forward-looking statements contained in this press release include statements referring to the expected opportunities in the asset-backed finance market, ABF I’s investment strategy and activities, and the expected benefits resulting from the integration of Brookfield and Oaktree.

Although Brookfield believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the United States and Canada, not presently known to Brookfield or that that Brookfield currently believes are not material, could cause actual results or events to differ materially from those contemplated or implied by forward-looking statements.

Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to Brookfield as of the date of this press release. Except as required by law, Brookfield undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered into a settlement agreement with OMass Therapeutics Limited (“OMass”) in relation to OMass’ past infringement of patents EP 3 408 286 B1 and GB 2 558 968 B relating to Nxera’s proprietary miniG platform technology. 

The settlement resolves the patent infringement proceedings brought by Nxera before the Patents Court of the High Court of Justice of England and Wales (Claim No: HP-2026-000015). Specific terms of the settlement agreement are confidential between the parties.

Nxera’s miniG technology forms a critical part of its NxWave™ GPCR-focused structure-based drug discovery platform. Nxera remains committed to protecting its proprietary technologies underpinning NxWave™ and will continue to monitor unauthorised use and take appropriate action, including enforcement proceedings where necessary, to protect such intellectual property.

–END–

About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies, powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations
Shinya Tsuzuki, VP, Head of Investor Relations
+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company to discuss third quarter earnings on November 3rd

VIRGINIA BEACH, Va., Oct. 01, 2026 (GLOBE NEWSWIRE) — AH Realty Trust (NYSE: AHRT) will report its earnings for the quarter ended September 30, 2026, at approximately 4:00 p.m. Eastern on Monday, November 2, 2026. At 8:30 a.m. Eastern on Tuesday, November 3, 2026, management will host a conference call and webcast to discuss earnings and other information.

To listen to the call, dial 1-833-461-5787 (toll-free dial-in number) or 1-585-542-9983 (toll dial-in number). The conference ID is 984 437 291. The conference call will also be available through the investors page of the Company’s website, AHRealtyTrust.com.

A telephonic replay will be available shortly after the conclusion of the call through Tuesday, December 1, 2026. This replay may be accessed by dialing 1-833-309-1852 and providing passcode 984 437 291. A replay of the webcast will also be available for 30 days beginning approximately two hours after the conclusion of the conference call.

About AH Realty Trust
AH Realty Trust (NYSE: AHRT) is a real estate investment trust (“REIT”) with over four decades of experience. The Company owns and operates high-quality retail and mixed-use office assets located primarily in the Mid-Atlantic and Southeastern United States. AH Realty Trust focuses on disciplined capital allocation and long-term value creation for shareholders. For more information visit AHRealtyTrust.com.

Contact:
Chelsea Forrest
AH Realty Trust
Executive Vice President of Investor Relations and Administration
Email: Chelsea.Forrest@ahrealtytrust.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Global Net Lease, Inc. (“GNL” or the “Company”) (NYSE: GNL / GNL PRA / GNL PRB / GNL PRD / GNL PRE) announced today that it declared a dividend of $0.190 per share of common stock payable on October 16, 2026, to common stockholders of record at the close of business on October 12, 2026.

Dividends authorized by the Company’s board of directors and declared by the Company are paid on a quarterly basis in arrears during the first month following the end of each fiscal quarter (unless otherwise specified) to common stockholders of record on the record date for such payment.

About Global Net Lease, Inc.
Global Net Lease, Inc. (NYSE: GNL) is a publicly traded real estate investment trust that focuses on acquiring and managing a global portfolio of income producing net lease assets across the United States, and Western and Northern Europe. Additional information about GNL can be found on its website at www.globalnetlease.com. 

Important Notice
The statements in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. The words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “expects,” “estimates,” “projects,” “potential,” “predicts,” “plans,” “intends,” “would,” “could,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and other factors, many of which are outside of the Company’s control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks that any potential future acquisition or disposition by the Company is subject to market conditions, capital availability and timing considerations and may not be identified or completed on favorable terms, or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in the Company’s forward-looking statements are set forth in the “Risk Factors” and “Quantitative and Qualitative Disclosures about Market Risk” sections in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.

Contacts:
Investor Relations
Email: investorrelations@globalnetlease.com

LUXEMBOURG, Oct. 01, 2026 (GLOBE NEWSWIRE) — Sompo, a leading global provider of commercial and consumer property and casualty (re)insurance, today announced the appointment of Scott Toland as Head of Commercial Lines, Insurance, Continental Europe.

Mr Toland will report to Ralph Brand, President, Insurance, Continental Europe & Turkey, and will be based in Zurich.

In his new role, Mr Toland will be responsible for defining and executing Sompo’s Commercial Lines underwriting strategy across Continental Europe. He will also oversee all underwriting activities across the region’s product lines, as well as business development functions, including distribution and client management, and risk control services.

Mr Toland has more than 25 years of insurance industry experience, having held a variety of increasingly senior roles in both the US and Europe. He joins Sompo from a large international insurer where, most recently, he served as Chief Underwriting Officer for EMEA.

Mr Brand said: “Scott’s appointment marks an important step in the continued development of our Commercial Lines platform in Continental Europe. His leadership experience, market insight and disciplined underwriting approach will help us build on our momentum and deliver even greater value to our clients and broker partners across the region.”

About Sompo
We are Sompo, a global provider of commercial and consumer property, casualty, and specialty insurance and reinsurance. Building on the 138 years of innovation of our parent company, Sompo Holdings, Inc., Sompo employs approximately 10,000 people around the world who use their in-depth knowledge and expertise to help simplify and resolve your complex challenges. Because when you choose Sompo, you choose The Ease of Expertise™.

“Sompo” refers to the brand under which Sompo International Holdings Ltd., a Bermuda-based holding company, together with its consolidated subsidiaries, operates its global property and casualty (re)insurance businesses. Sompo International Holdings Ltd. is an indirect wholly-owned subsidiary of Sompo Holdings, Inc., one of the leading property and casualty groups in the world with excellent financial strength as evidenced by ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard & Poor’s. Shares of Sompo Holdings, Inc. are listed on the Tokyo Stock Exchange.

To learn more please follow us on LinkedIn or visit sompo-intl.com.

Sompo contacts:
Mike Jones
Global Head of Media Relations, Sompo
M: +44 7765 901899
E: mijones@sompo-intl.com

Alexandra Brändli
Head of Marketing & Communications,
Insurance, Continental Europe, Sompo
M: +41 (0) 79 606 04 49
E: abraendli@sompo-intl.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.